JP Patent

JP2017538706A — 選択的s1p1レセプターアゴニストの投与法

Assigned to Actelion Pharmaceuticals Ltd · Expires 2017-12-28 · 8y expired

What this patent protects

本発明は、(R)−5−[3−クロロ−4−(2,3−ジヒドロキシ−プロポキシ)−ベンゾ[Z]イリデン]−2−([Z]−プロピルイミノ)−3−o−トリル−チアゾリジン−4−オンの投与法に関する。【選択図】 なし

USPTO Abstract

本発明は、(R)−5−[3−クロロ−4−(2,3−ジヒドロキシ−プロポキシ)−ベンゾ[Z]イリデン]−2−([Z]−プロピルイミノ)−3−o−トリル−チアゾリジン−4−オンの投与法に関する。【選択図】 なし

Drugs covered by this patent

Patent Metadata

Patent number
JP2017538706A
Jurisdiction
JP
Classification
Expires
2017-12-28
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.